{
    "Clinical Trial ID": "NCT00454805",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cediranib 45 mg",
        "  Cediranib 45 mg+Fulvestrant 250 mg",
        "  Patients randomised to the investigational arm (fulvestrant + cediranib) received treatment according to the following schedule:",
        "  Day 1: fulvestrant 500 mg im",
        "  Day 15: fulvestrant 250 mg im",
        "  Day 29, and every 28 days thereafter: fulvestrant 250 mg im",
        "  and daily: cediranib 45 mg (administered orally)",
        "INTERVENTION 2: ",
        "  Placebo",
        "  Placebo+Fulvestrant 250 mg",
        "  Patients randomised to the control arm (fulvestrant + placebo) received treatment according to the following schedule:",
        "  Day 1: fulvestrant 500 mg im",
        "  Day 15: fulvestrant 250 mg im",
        "  Day 29, and every 28 days thereafter: fulvestrant 250 mg im",
        "  and daily: placebo to match cediranib (administered orally)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Written informed consent",
        "  Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease",
        "  One or more evaluable lesions",
        "Exclusion Criteria:",
        "  Prior hormonal therapy with fulvestrant",
        "  More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer",
        "  Prior biologic therapy for ABC including Anti-VEGF agents",
        "  Radiation therapy within 4 weeks prior to provision of consent"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival",
        "  Number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression.",
        "  Time frame: RECIST performed at screening and every 8 weeks through to progression or discontinuation whichever is earliest.",
        "Results 1: ",
        "  Arm/Group Title: Cediranib 45 mg",
        "  Arm/Group Description: Cediranib 45 mg+Fulvestrant 250 mg",
        "  Patients randomised to the investigational arm (fulvestrant + cediranib) received treatment according to the following schedule:",
        "  Day 1: fulvestrant 500 mg im",
        "  Day 15: fulvestrant 250 mg im",
        "  Day 29, and every 28 days thereafter: fulvestrant 250 mg im",
        "  and daily: cediranib 45 mg (administered orally)",
        "  Overall Number of Participants Analyzed: 31",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Days  223        (129 to 340)",
        "Results 2: ",
        "  Arm/Group Title: Placebo",
        "  Arm/Group Description: Placebo+Fulvestrant 250 mg",
        "  Patients randomised to the control arm (fulvestrant + placebo) received treatment according to the following schedule:",
        "  Day 1: fulvestrant 500 mg im",
        "  Day 15: fulvestrant 250 mg im",
        "  Day 29, and every 28 days thereafter: fulvestrant 250 mg im",
        "  and daily: placebo to match cediranib (administered orally)",
        "  Overall Number of Participants Analyzed: 31",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Days  112        (59 to 329)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 15/31 (48.39%)",
        "  Intracardiac Thrombus 1/31 (3.23%)",
        "  Diarrhoea 2/31 (6.45%)",
        "  Nausea 2/31 (6.45%)",
        "  Vomiting 2/31 (6.45%)",
        "  Ascites 0/31 (0.00%)",
        "  Ileus 1/31 (3.23%)",
        "  Small Intestinal Obstruction 1/31 (3.23%)",
        "  Multi-Organ Failure 0/31 (0.00%)",
        "  Sepsis 1/31 (3.23%)",
        "  Weight Decreased 1/31 (3.23%)",
        "  Dehydration 2/31 (6.45%)",
        "  Hypokalaemia 0/31 (0.00%)",
        "Adverse Events 2:",
        "  Total: 4/31 (12.90%)",
        "  Intracardiac Thrombus 0/31 (0.00%)",
        "  Diarrhoea 0/31 (0.00%)",
        "  Nausea 0/31 (0.00%)",
        "  Vomiting 0/31 (0.00%)",
        "  Ascites 1/31 (3.23%)",
        "  Ileus 0/31 (0.00%)",
        "  Small Intestinal Obstruction 0/31 (0.00%)",
        "  Multi-Organ Failure 1/31 (3.23%)",
        "  Sepsis 0/31 (0.00%)",
        "  Weight Decreased 0/31 (0.00%)",
        "  Dehydration 0/31 (0.00%)",
        "  Hypokalaemia 1/31 (3.23%)"
    ]
}